{"id":"F2017L00623","name":"National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)","slug":"national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":96397,"registerId":"commonwealth-F2017L00623-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)","content":"![](image.001.png)\n\nPB 41 of 2017\n\nNational Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4)\n\nNational Health Act 1953\n\nI, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.\n\nDated 30 May 2017\n\nLOUISE CLARKE\n\nAssistant Secretary\n\nPharmaceutical Evaluation Branch\n\nPharmaceutical Benefits Division\n\nDepartment of Health\n\nPart 1 Preliminary\n\n1 Name of Determination\n\n(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4).\n\n(2) This Determination may also be cited as PB 41 of 2017.\n\n2 Commencement\n\nThis Determination commences on 1 June 2017.\n\n3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010\n\nSchedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).\n\n  \n\nSchedule 1 Amendments\n\n(Section 3)\n\n\\[1\\] Schedule 1, after item dealing with Codeine\n\nOmit\n\nColestipol\n\n\\[2\\] Schedule 1, after item dealing with Essential amino acids formula with vitamins and minerals\n\nOmit\n\nEtanercept\n\n\\[3\\] Schedule 1, after item dealing with Flupenthixol Decanoate\n\nOmit\n\nFluphenazine Decanoate\n\nFluticasone\n\nInsert\n\nFluticasone furoate with vilanterol\n\n\\[4\\] Schedule 1, after item dealing with Romiplostim\n\nOmit\n\nRosiglitazone\n\n\\[5\\] Schedule 1, after item dealing with Zidovudine\n\nOmit\n\nZonisamide\n\n\\[6\\] Schedule 2, after item dealing with Flutamide\n\nInsert\n\nFluticasone\n\nFluticasone with Salmeterol\n\n\\[7\\] Schedule 2, after item dealing with Zolmitriptan\n\nInsert\n\nZonisamide","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":2248},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This is a routine administrative update to pharmaceutical listings, consistent with the original purpose of managing formulary categorisation and price disclosure under the PBS."},"complexity_factors":["Very short instrument containing only 7 mechanical amendments (omissions and insertions)","Assumes knowledge of F1/F2 formulary distinctions and the parent Determination (PB 93 of 2010)","Uses legislative shorthand ('after item dealing with...') requiring cross-reference to base instrument"],"plain_english_summary":"This determination updates the lists of subsidised medicines under the Pharmaceutical Benefits Scheme (PBS). The PBS divides medicines into two baskets: **F1** (single-brand medicines, usually still under patent) and **F2** (multi-brand or generic medicines with multiple suppliers).\n\n**What it does:**\n- **Removes** five medicines from the single-brand list (F1): *Colestipol*, *Etanercept*, *Fluphenazine Decanoate*, *Rosiglitazone*, and plain *Fluticasone*\n- **Moves** two medicines to the multi-brand list (F2): *Fluticasone* and *Zonisamide* — this happens when generic alternatives become available\n- **Adds** a new combination inhaler to F1: *Fluticasone furoate with vilanterol*\n- **Adds** *Fluticasone* and *Fluticasone with Salmeterol* to F2\n\n**Why it matters:** When medicines shift to F2, competition between manufacturers usually drives down prices. This changes what patients pay as a co-payment and how much the government subsidises."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017","history":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017/history","analysis":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017/analysis","conflicts":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017/conflicts","importantCases":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017/important-cases","documents":"/api/acts/national-health-listed-drugs-on-f1-or-f2-amendment-determination-2017-no-4-pb-41-of-2017/documents"}}